Advertisement for orthosearch.org.uk
Results 1 - 2 of 2
Results per page:
The Journal of Bone & Joint Surgery British Volume
Vol. 86-B, Issue 5 | Pages 719 - 725
1 Jul 2004
Matsumine A Myoui A Kusuzaki K Araki N Seto M Yoshikawa H Uchida A

We reviewed the results of 51 patients with benign bone tumours treated by curettage and implantation of calcium hydroxyapatite ceramic (CHA). The mean follow-up was 11.4 years (10 to 15.5). Post-operative fractures occurred in two patients and three had local recurrences; three had slightly limited movement of the adjacent joint and one had mild osteoarthritis. There were no allergic or neoplastic complications. In all cases, radiographs showed that the CHA was well incorporated into the host bone.

Statistical analysis showed that absorption of the implanted CHA was greater in males (odds ratio, 6.2; 95% CI, 1.6 to 23.7) and younger patients (odds ratio, 0.6 for increase in age of 10 years; 95% CI, 0.91 to 0.99). However, the implanted CHA was not completely absorbed in any patient.

We conclude that CHA is a useful and safe bone substitute for the treatment of benign bone tumours.


The Journal of Bone & Joint Surgery British Volume
Vol. 86-B, Issue 4 | Pages 607 - 612
1 May 2004
Asano N Yamakazi T Seto M Matsumine A Yoshikawa H Uchida A

We investigated the rates of expression of bone morphogenetic protein-2 (BMP-2) in 29 adult patients with high-grade malignant fibrous histiocytoma of soft tissue, using the BMP-2-specific monoclonal antibody, AbH3b2/17, and found that they ranged from 1.9% to 78.9%. The survival at five years of the groups expressing high (≥30%) and low (< 30%) levels of BMP-2 was 85.7% and 36.3%, respectively. Multivariable analysis showed that only BMP-2 had prognostic significance for continuous disease-free survival and for overall survival (p < 0.05). Our findings indicate that over-expression of BMP-2 in malignant fibrous histiocytoma of soft tissue is the most reliable prognostic indicator of the parameters assessed.